Imagine if you could connect data, and people, to improve human health. 

We understand that connections matter. Between data, between stakeholders, between patients and the system they live in. And we see that the explosion of Big Data in healthcare – coming from a seemingly endless stream of sources – is making those connections harder, but also somehow more important, by the minute. 

Because IQVIA is The Human Data Science Company™, we are also at the leading edge of understanding how capturing, connecting, and most importantly protecting, this non-identified human data is the key to improving human health. 

The potential for Digital Health is exciting. But so is the reality.

The Evidence. 

Clinical evidence of the efficacy of Digital Health has grown substantially in the last decade. Evidence is being generated through trials, pilots and evaluations based on Real-World Evidence. That evidence is then being made available for shared learning and faster and more consistent adoption of digital health tools. 

The Innovations. 

The development of Digital Health tools, from digital therapeutics to wearable sensors to digital biomarkers, is thriving. But it’s not just the what that matter in Digital Health, it’s also the how. We see innovators increasingly knowing the steps and standards they need to follow to test their technology and generate evidence that is relevant and evaluated consistently to support payer decision-making. 

The Adoption. 

We’re not at the beginning. From drug development to commercialization, adoption of Digital Health is increasing across the healthcare landscape. Because we now know, based on research from the IQVIA Institute for Human Data Science, that the value of collecting and connecting non-identifiable data on human health, from inside and outside the healthcare environment, has surpassed the barriers.  And so informed providers have access to the right evidence-based technology tailored to their patient’s needs and users can provide real-world data to ensure ongoing surveillance of the technology and its safety and efficacy. 

Digital Health Stories

Validating a patient support app
To evaluate the effectiveness of a mobile app in improving patient persistence in staying on cholesterol lowering therapy, IQVIA undertook a retrospective, matched cohort study. We de-identified the list of the app users and linked it to our prescription database, creating a corresponding control group based on therapy type and key demographics. We then calculated therapy persistence using drug refill status for six months following the first treatment. The investigation showed that patients using the digital health app had a 15 percent higher persistence rate than those without it. The company used these insights to design a randomized study to build an even stronger base of evidence.
Social listening as a window into patient behavior
To understand treatment switching patterns and the underlying drivers of switching decisions in multiple sclerosis, IQVIA combined “automated listening” and processing with manual analysis to gather data from social media websites, advocacy group forums and patient blogs. We compared language referring to switching between oral, injectable and IV therapies and extracted over 25,000 data points – more than 10,000 of which were relevant to the study objectives. The study revealed that treatment switching was most common for injectable therapy users, primarily due to side effects and lack of efficacy. Following our analysis, the company has invested in developing a command center to conduct further research via automated social listening combined with manual analysis.
Digital Biotech Podcast
Podcast interview featuring Nelia Padilla, IQVIA Global Digital Health Lead. She discusses working at the unique intersection of the R&D and Commercial landscapes with a particular focus on how Digital Health is impacting both.
Connecting the Digital Dots
The Growing Value of Digital Health
On-Demand Webinar
Digital Health Strategy for Your Brand: When and How to Optimize Success